L M Hylind
Overview
Explore the profile of L M Hylind including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang V, Geiman D, Hubbard W, Spannhake E, Hylind L, Hamilton S, et al.
Prostaglandins Other Lipid Mediat
. 2000 Feb;
60(1-3):83-96.
PMID: 10680778
Recent studies indicate that sulindac, a nonsteroidal anti-inflammatory drug (NSAID), lowers mucosal prostanoid levels and regresses colorectal adenomas in patients with familial adenomatous polyposis (FAP). To determine whether they are...
2.
Keller J, Offerhaus G, Polak M, Goodman S, Zahurak M, Hylind L, et al.
Gut
. 1999 Nov;
45(6):822-8.
PMID: 10562579
Background: Sulindac regresses colorectal adenomas in patients with familial adenomatous polyposis (FAP), although the mechanism of polyp regression is unclear. Aims: To determine whether differences occur in alteration of rectal...
3.
Yang V, Shields J, Hamilton S, Spannhake E, Hubbard W, Hylind L, et al.
Cancer Res
. 1998 May;
58(8):1750-3.
PMID: 9563494
Recent studies indicate that nonsteroidal anti-inflammatory drugs have a chemopreventive effect against colorectal neoplasia. Nonsteroidal anti-inflammatory drugs inhibit cyclooxygenases, principal enzymes that mediate the formation of prostanoids. To determine whether...
4.
Giardiello F, Spannhake E, DuBois R, Hylind L, Robinson C, Hubbard W, et al.
Dig Dis Sci
. 1998 Mar;
43(2):311-6.
PMID: 9512123
Recent evidence suggests that nonsteroidal antiinflammatory drugs (NSAIDs) may prevent colorectal cancer. The mechanism of action of NSAIDs in chemoprevention is unknown but may be linked to their effect on...
5.
Giardiello F, Brensinger J, Petersen G, Luce M, Hylind L, Bacon J, et al.
N Engl J Med
. 1997 Mar;
336(12):823-7.
PMID: 9062090
Background: The use of commercially available tests for genes linked to familial cancer has aroused concern about the impact of these tests on patients. Familial adenomatous polyposis is an autosomal...
6.
Giardiello F, Hamilton S, Hylind L, Yang V, Tamez P, Casero Jr R
Cancer Res
. 1997 Jan;
57(2):199-201.
PMID: 9000553
Familial adenomatous polyposis (FAP), due to germ-line mutation of the adenomatous polyposis coli (APC) gene, is characterized by development of colorectal adenomas and ultimately colorectal cancer. The usefulness of ornithine...
7.
Giardiello F, Offerhaus J, Tersmette A, Hylind L, KRUSH A, Brensinger J, et al.
Gut
. 1996 Apr;
38(4):578-81.
PMID: 8707091
Background: Sulindac, a non-steroidal anti-inflammatory drug, causes regression of colorectal adenomas in patients with familial adenomatous polyposis (FAP) but the response is variable. Specific clinical factors predictive of sulindac induced...
8.
Giardiello F, Hamilton S, KRUSH A, Piantadosi S, Hylind L, Celano P, et al.
N Engl J Med
. 1993 May;
328(18):1313-6.
PMID: 8385741
Background: Familial adenomatous polyposis is an autosomal dominant disorder characterized by the formation of hundreds of colorectal adenomas and eventual colorectal cancer. Administration of the nonsteroidal antiinflammatory drug sulindac has...